Document is current

Article History

Received: 4 December 2023

Accepted: 14 March 2024

First Online: 16 April 2024

Declarations

:

: Roger Chen: was a speaker and/or attendee of advisory boards and has received research funding from: Abbott, Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk; Azizul Hasan Aamir: is a member of the speaker bureau for Sanofi, Novo Nordisk, Getz Pharma, Hilton Pharma and CCL Pharma; Mohammod Feroz Amin: has been a speaker and/or on advisory boards or a recipient of research funding for Eli Lilly, Novo Nordisk, Synovia ( Sanofi), ACI, Beximco and Incepta Pharmaceuticals Bangladesh; Pongamorn Bunnag: has acted as a speaker or advisor/consultant for AstraZeneca, Boehringer Ingelheim, Zuellig Pharma, Novo Nordisk, Sanofi, Abbott, LG Lifesciences, Bayer and Celltrion; Siew Pheng Chan: has received honoraria as speaker and advisory board member from: Abbott, AstraZeneca, Boerhinger-Ingelheim, Merck, Novo Nordisk, Servier, Zuellig Pharma Therapeutics; Lixin Guo: has participated as an advisory board member/consultant for Abbott, AstraZeneca, Bayer, Boehringer-Ingelheim, Dreisamtech, Dongbao, Eli Lilly, Gan & Lee, Hansoh, Hengrui, Huadong Medicine, Hua Medicine, Innovent, Janssen, Novartis, Novo Nordisk, Merck, Pfizer, Sanofi, Synapsor, Takeda, Zense and 3sbio, and has received research funding or grants from the National Natural Science Foundation of China, the Beijing Natural Science Foundation, Abbott, AstraZeneca, Bayer, Dreisamtech, Eli Lilly, Hansoh, Hengrui, Huadong Medicine, Hua Medicine, Innovent, Meitekanger tech, Novo Nordisk, Salubris, Sanofi, Synapsor and Zense; Mohammad E. Khamseh: has received honoraria and research grants from Novo Nordisk, Roche, Sanofi and Merck; Viswanathan Mohan: has received honoraria and research grants from Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim and several Indian Pharma companies; Nemencio Nicodemus Jr.: has received speaker honoraria from Novo Nordisk and Sanofi; Anthony Roberts: has received research funding or honorarium from Eli Lilly, AstraZeneca, Novo Nordisk, MSD, Boehringer Ingelheim, Janssen, Novartis, Lexicon Pharmaceuticals and Inc., Sanofi; Tri Juli Edi Tarigan: has received honorarium as speaker/consultant, support for research/clinical trial/attendance at educational meetings from AstraZeneca, Sanofi, Novo Nordisk, Boehringer Ingelheim, Servier, Kalbe Pharma, Sanbe, ZP Pharma and more; Kyu-Chang Won: has received research grants and speaker honoraria from Novo Nordisk, Eli Lilly, and Sanofi; Roopa Mehta: has acted as a speaker or advisor/consultant for Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Silanes. Mohammad E. Khamseh is an Editorial Board member of Diabetes Therapy. Mohammad E. Khamseh was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.